A phase III study of Eryaspase as second line treatment for patients with metastatic pancreatic cancer

Trial Profile

A phase III study of Eryaspase as second line treatment for patients with metastatic pancreatic cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs ERY-ASP (Primary)
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors ERYtech Pharma
  • Most Recent Events

    • 06 Nov 2017 According to an ERYTECH media release, this trial is expected to initiate in the third quarter of 2018.
    • 11 Sep 2017 According to an ERYtech Pharma media release, the company expects the potential launch of this study over next twelve months.
    • 11 Sep 2017 According to an ERYtech Pharma media release, the company expects to discuss the design of this potential phase 3 study with the U.S. FDA in the coming weeks (scheduled for October) and the Committee for Medicinal Products for Human Use (CHMP) before the end of the year (later in 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top